All News

RheumNow Podcast square

Moral Distress (3.27.2026)

Jack Cush, MD

Dr. Jack Cush reviews the journal reports and news from RheumNow.com.  This week we discuss moral distress, FM in PsA, Lyme Vax is back & hidden but tangible benefits of the MDHAQ.

Read Article
psoriasis.NPF_.png

Systemic Treatments for Chronic Plaque Psoriasis

Jack Cush, MD

JAMA Dermatology has published a review of the pharmacologic landscape on managing adults with moderate to severe plaque psoriasis.

Read Article
Biologics.new

Spotty Medicare Coverage for Newer Rheumatoid Arthritis Meds

MedPage Today

Medicare coverage of targeted disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA) -- both under Medicare Advantage and in separate Part D plans -- is likely to leave many patients wanting, researchers found.

Read Article
RheumNow Podcast square

Rheumatology Pitfalls (3.20.2026)

Jack Cush, MD

Dr. Jack Cush reviews the regulatory actions, news and journal reports from this past week on RheumNow.com.

Read Article
guidelines.jpg (keep)

2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management

Jack Cush, MD

The European Alliance of Associations for Rheumatology (EULAR) has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous recommendations.

Read Article
FDA%20approved.jpg (keep)

TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis

Jack Cush, MD

On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active psoriatic arthritis (PsA) based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials.

Read Article
RheumNow Podcast square

UBER Rheumatology Ride (3.6.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com

Read Article
RheumNow Podcast square

SATISFACTION (2.27.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
RheumNow Podcast square

Referral Rules to Live By (2.20.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Highlights include referral rules, combination biiologics in psoriasis and don't use JAK inhibitors in pregnancy.

Read Article
takayasu.jpg

Diagnosing and Managing GCA and Takayasu’s Arteritis

Adela Castro, MD

Giant-cell arteritis and Takayasu’s arteritis are both large-vessel vasculitides, but each brings its own diagnostic and management challenges. Many of the difficulties overlap because they are rare, heterogeneous, and lack perfect diagnostic tests or specific biomarkers.

Read Article
Basic, full-read overview of "JAK inhibitors: risks and safety principles" from the Pharmaceutical Journal. Addresses MOA, indications, warnings, monitoring, adverse effects, interactions, Serious AEs, vaccination and best practices. https://t.co/6kZCde1NdF https://t.co/NlEKtvUGPa

Links:

Dr. John Cush RheumNow ( View Tweet)
Basic, full-read overview of "JAK inhibitors: risks and safety principles" from the Pharmaceutical Journal. Addresses MOA, indications, warnings, monitoring, adverse effects, interactions, Serious AEs, vaccination and best practices. https://t.co/qrqeu1CzRg https://t.co/7qIszLwUrf

Links:

Dr. John Cush RheumNow ( View Tweet)
TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active PsA based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. https://t.co/a6rmortnoS
Dr. John Cush RheumNow ( View Tweet)
FDA has approved deucravacitinib (Sotyktu) the Treatment of Adults with Active Psoriatic Arthritis based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. Sotyktu is the only tyrosine kinase 2 (TYK2) inhibitor to be approved for PsA https://t.co/8xBrgPfENH
Dr. John Cush RheumNow ( View Tweet)
DERM on RheumNow PODCAST (February 2026) The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, and other CTD skin disorders. dermatology drugs, biologics, JAKs - their use, efficacy, https://t.co/4ub0MeY9vF
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 1553 IBD pts taking biologics or JAKi, w/ 5+ yrs of F/U, 6.8% developed MSK Sxs, with one-third subsequently Dx w/ SpA. HLA-B27 positivity (HR 3.7) and higher UC disease activity (HR 1.57) were associated with an increased risk of SpA. https://t.co/I2YSOLhkAb
Dr. John Cush RheumNow ( View Tweet)
BREAKING NEWS: How many patients with RA achieve and maintain remission with a JAKi? Find out in the RheumNow poster hall with data from the latest real-world study of long-term RA remission. Sponsored by AbbVieMedical Affairs + Health Impact. https://t.co/PPYVfz3tuC https://t.co/Boq8V3qqFp

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read review of JAK inhibitors. JAK inhibitors have a reasonably rapid onset of action and a short half-life, which facilitates management of any adverse effects. The half-life of Tofacitinib, Baricitinib & Upadacitinib is 3 hrs, 13 hrs. & 9-14hrs. https://t.co/C9t2SQ3Juq
Dr. John Cush RheumNow ( View Tweet)
Full read review of JAK inhibitors. JAK inhibitors have a reasonably rapid onset of action and a short half-life, which facilitates management of any adverse effects. The half-life of Tofacitinib, Baricitinib & Upadacitinib is 3 hrs, 13 hrs. & 9-14hrs. https://t.co/jKO2LL2TVC
Dr. John Cush RheumNow ( View Tweet)
Can I Use JAK Inhibitors During Pregnancy? Short answer: Not yet. https://t.co/E9yrWR5zTG https://t.co/NLy6OibkYH

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×